These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 23223053)
21. Regulatory watch: FDA guidance on co-developing investigational drugs. Nat Rev Drug Discov; 2011 Feb; 10(2):86. PubMed ID: 21283094 [No Abstract] [Full Text] [Related]
22. Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe. Roberts SA; Allen JD; Sigal EV Health Aff (Millwood); 2011 Jul; 30(7):1375-81. PubMed ID: 21680577 [TBL] [Abstract][Full Text] [Related]
29. FDA guidance on prophylactic DNA vaccines: analysis and recommendations. Klinman DM; Klaschik S; Tross D; Shirota H; Steinhagen F Vaccine; 2010 Apr; 28(16):2801-5. PubMed ID: 19941989 [TBL] [Abstract][Full Text] [Related]
30. [Drug development in Japan from the viewpoints of global pharmaceutical companies]. Seriu T Rinsho Ketsueki; 2009 Jul; 50(7):556-62. PubMed ID: 19638723 [No Abstract] [Full Text] [Related]
31. Analysis of pharmaceutical safety-related regulatory actions in Japan: do tradeoffs exist between safer drugs and launch delay? Yamada T; Kusama M; Hirai Y; Arnold F; Sugiyama Y; Ono S Ann Pharmacother; 2010 Dec; 44(12):1976-85. PubMed ID: 21098757 [TBL] [Abstract][Full Text] [Related]
32. The FDA's drug review process: ensuring drugs are safe and effective. Meadows M FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298 [No Abstract] [Full Text] [Related]
34. [New perspective for drug discovery and clinical development in kidney disease]. Miyata T; Kikuchi K; Saito K Nihon Jinzo Gakkai Shi; 2012; 54(5):610-4. PubMed ID: 22991841 [No Abstract] [Full Text] [Related]
35. Communicating with the FDA: the "third rail" of a new model for drug development. Stanski DR; Orloff JJ J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890 [No Abstract] [Full Text] [Related]
36. FDA not NIH can speed new drugs. Miller HI Nature; 2011 Apr; 472(7342):169. PubMed ID: 21490657 [No Abstract] [Full Text] [Related]
37. Understanding the FDA guidance on adaptive designs: historical, legal, and statistical perspectives. Liu Q; Chi GY J Biopharm Stat; 2010 Nov; 20(6):1178-219. PubMed ID: 21058114 [TBL] [Abstract][Full Text] [Related]
38. Fragment-Based Drug Discovery--CHI's Fourth Annual Meeting. 6-7 April 2009, San Diego, CA, USA. Seneci P IDrugs; 2009 Jun; 12(6):353-7. PubMed ID: 19517314 [No Abstract] [Full Text] [Related]
39. Investigational drug tracking: phases I-III and NDA submissions--Part II. Grant KL Hosp Pharm; 1994 Oct; 29(10):900, 902-4, 906-11 passim. PubMed ID: 10137850 [TBL] [Abstract][Full Text] [Related]
40. Trends in development and approval times for new therapeutics in the United States. Reichert JM Nat Rev Drug Discov; 2003 Sep; 2(9):695-702. PubMed ID: 12951576 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]